Novel CRISPR-mediated genome editing platformto develop safe, efficient and durable cures for genetic disease
SCRIPT Biosciences was founded in 2020 with the goal of developing potentially curative therapies for rare genetic disorders using our proprietary gene-editing platform
Our lead platform technology, CasPlus uses CRISPR based constructs to efficiently edit diverse mutation types responsible for the majority of monogenetic disorders
CasPlus has wide applicability and superior editing efficiency compared to existing technologies with the ability to produce 1 -3 base pair insertions in a predictable and template-free approach and supported by encouraging pre-clinical data
Multiple patents have been filed or are under development. Research and clinical development are led by recognized world leaders.
TheCasPlusPlatform is Designed for Predictable and Template-Free Gene Editing
Site-specific double-strand break
Precise 1 to 3 base pair insertions
Indels created in a DNA repair template-free manner
Uniquely Differentiated Within the Gene Editing Landscape
Double Strand Break
Controlled DNA Repair
Favorable editing to indel ratios
Off Target Edits
We seek a Research Associate/Lab Manager to support our therapeutic gene editing discovery efforts using the CasPlus platform.
Professor & Director, NYU Comprehensive Epilepsy Center
Glenn Fishman, M.D.
Professor & Director, NYU Division of Cardiology
Michael Jasulavic, MS
MiaMed (acquired by Amicus Therapeutics)
Scientific Advisory Board
Wendy Chung, M.D.
National Academy of Medicine Association of American Physicians
Paul Modrich, Ph.D.
National Academy of Sciences 2015 Nobel Prize in Chemistry
Darren Monckton, Ph.D.
Professor of Human Genetics
News, Publications, Materials
May 17, 2022
The CasPlus Gene Editing Platform Technology can Correct Mutations Associated with Duchenne's Muscular Dystrophy and Cystic Fibrosis with High Efficiency and Exceptionally Low Rates of On-Target DNA Damages.